JET-RANGER Trial - JETStream Atherectomy With Adjunctive Paclitaxel-Coated Balloon Angioplasty vs Plain Old Balloon Angioplasty Followed by Paclitaxel-Coated Balloon

NCT ID: NCT03206762

Last Updated: 2023-10-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 47 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-28
• Study Completion Date: 2023-05-16

Brief Summary

A prospective, multicenter, randomized study evaluating the use of Jetstream Atherectomy (JS) followed by DCB in comparison to the use of plain old balloon angioplasty (POBA) followed by DCB alone in the treatment of complex lesions in femoropopliteal arteries in subjects with claudication (Rutherford Clinical Category (RCC) of 2-4) (complex lesions are defined as long (≥ 10 cm) lesions, or moderately or highly calcified lesions, or chronic total occlusions irrespective of length).

Conditions

Peripheral Vascular Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB

Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB

Group Type: EXPERIMENTAL

Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm

Intervention Type: DEVICE

Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm

POBA+DCB (Ranger or IN.PACT)

POBA and then DCB treatment (Ranger or IN.PACT)

Group Type: ACTIVE_COMPARATOR

Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm

Intervention Type: DEVICE

Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm

Interventions

Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm

Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Has a Rutherford Clinical Category of 2 - 4.

2. Is willing and capable of complying with all follow-up evaluations at the specified times (including an angiogram at the 1-year follow-up visit).

3. Is ≥ 18 years old.

4. Is able and willing to provide written informed consent prior to study specific procedures.

1. Has evidence at the target lesion of ≥ 70% de novo stenosis of a. ≥ 10 cm length, or b. any chronic total occlusion (> 1 month by history or known by conventional or CT angiography or arterial duplex ultrasound) in the SFA (at least 1 cm from the bifurcation of the profunda) and/or popliteal artery, or 3. at least grade 2 or higher calcification as defined by the peripheral arterial calcium scoring system (PACCS)26

2. Has evidence of at least one runoff vessel to the ankle/foot of the limb to be treated that does not have significant (< 70%) stenosis during the index procedure.

3. Has a reference vessel diameter of 4 - 7 mm.

4. Has a target lesion an exchangeable guidewire can cross via the true lumen (without using a re-entry device or a subintimal approach).

Exclusion Criteria

1. Has one or more of the contraindications listed in the JetStream or Ranger IFUs.

2. Has a contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used (that cannot be reasonably substituted).

3. Is expected to require cilostazol (Pletal) during the one-year follow-up period.

4. Has a hypersensitivity to contrast material that cannot be adequately pretreated.

5. Has known hypersensitivity to treatment device materials including paclitaxel or nitinol.

6. Has known uncontrollable hypercoagulable condition, or refuses blood transfusion.

7. Has life expectancy of less than 24 months.

8. Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing.

9. Has surgical or endovascular procedure of the target vessel within 30 days prior to the index procedure.

10. Has any planned surgical intervention (requiring hospitalization) or endovascular procedure within 30 days after the index procedure.

11. Is currently participating in an investigational drug or another device study that may clinically interfere with the study outcomes.

12. Has any co-morbid condition that in the judgment of the physician precludes safe percutaneous intervention.

13. Has had a previous peripheral bypass affecting the target vessel (allowable for physician to pass through bypass graft in aorta-iliac region to get to the target lesion).

14. Has chronic renal insufficiency (eGFR < 30 ml/min or creatinine ≥ 2.5 including dialysis patients).

15. Has planned laser, cryo, TurboHawk or any other treatment except study treatment within 30 days after the index procedure.

16. Has had superficial thrombophlebitis or deep venous thrombus within 30 days prior to index procedure.

17. Has had a stroke within 3 months prior to index procedure.

18. Has had a myocardial infarction within 1 month prior to index hospitalization

19. Has history of significant gastrointestinal bleeding in the past 2 months prior to index procedure, or any history of hemorrhagic diathesis.

20. Has a known or suspected systemic infection at the time of the index procedure.

21. Patients with ipsilateral Iliac and CFA disease are allowed in the study but these lesions have to be treated successfully first (<30% residual) before patient can be enrolled. Treatment as per investigator's preference.

22. Aneurysm located in the target vessel or aneurysmal vessel

1. Has < 70% stenosis prior to treatment of the target lesion.

2. Has in-stent restenosis of the target lesion.

3. Has an acute intraluminal thrombus within the target lesion.

4. Has an aneurysmal target vessel

5. Patient has already been enrolled in the study or any other study that by the investigator judgment may interfere with the outcome of this trial

6. Has two or more lesions that require treatment in the target vessel. Lesions have to be separated by > 5 cm in order to be considered different lesions. Only one lesion per target vessel can be enrolled during the index procedure

7. Has disease that precludes safe advancement of the JS device to the target lesion.

8. P3 segments of the popliteal vessel.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Midwest Cardiovascular Research Foundation

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nicolas Shammas, MD, Research Director

Role: STUDY_DIRECTOR

MCRF

Locations

Midwest Cardiovascular Research Foundation

Davenport, Iowa, United States

Countries

United States

Other Identifiers

MCRF-S-001-2015

Identifier Type: -

Identifier Source: org_study_id